Figure 2.
Relapse risk according to MRD level. RFS for participants with no detectable FLT3-ITD MRD is compared with RFS for participants with increasing levels of MRD. No MRD refers to no detectable MRD before or after HCT; MRD6 indicates mutant reads per total reads of ≥10−6 but <10−5; MRD5 indicates mutant reads per total reads of ≥10−5 but <10–4; and MRD4 indicates mutant reads per total reads of ≥10−4. (A) Placebo arm. (B) Gilteritinib arm. (C) Forest plot of cumulative incidence of relapse for gilteritinib vs placebo by level of MRD. 95% CI, 95% confidence interval; HR, hazard ratio; NE, not estimable.

Relapse risk according to MRD level. RFS for participants with no detectable FLT3-ITD MRD is compared with RFS for participants with increasing levels of MRD. No MRD refers to no detectable MRD before or after HCT; MRD6 indicates mutant reads per total reads of ≥10−6 but <10−5; MRD5 indicates mutant reads per total reads of ≥10−5 but <10–4; and MRD4 indicates mutant reads per total reads of ≥10−4. (A) Placebo arm. (B) Gilteritinib arm. (C) Forest plot of cumulative incidence of relapse for gilteritinib vs placebo by level of MRD. 95% CI, 95% confidence interval; HR, hazard ratio; NE, not estimable.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal